Comparable Renal Function at 6 Months with Tacrolimus Combined with Fixed-Dose Sirolimus or MMF: Results of a Randomized Multicenter Trial in Renal Transplantation
Table 3
Selected secondary endpoints.
Tacrolimus/Sirolimus
Tacrolimus/MMF
Acute Rejection, Number (%)
82 (25.8)
77 (24.4)
Biopsy confirmed acute rejection, Number (%):
48
39
Spontaneously resolving
1 (0.3)
0 (0.0)
Corticosteroid sensitive
34 (10.7)
32 (10.1)
Corticosteroid resistant
14 (4.4)
8 (2.5)
Resolved with further treatment
12 (3.8)
8 (2.5)
Other
1 (0.3)
0 (0.0)
Histological grade, Number (%):
Mild (Banff I)
30 (9.4)
20 (6.3)
Moderate (Banff II)
17 (5.3)
17 (5.4)
Severe (Banff III)
1 (0.3)
2 (0.6)
Patient , %
99.0
99.0
Graft , %
92.7
93.3
FAS than one BCAR episode was reported for some patients. -Meier estimates.